Location History:
- Westborough, MA (US) (1996 - 2005)
- Sarasota, FL (US) (1998 - 2010)
- Sarosota, FL (US) (2011)
Company Filing History:
10 out of 322 
2 out of 34 
1 out of 130 
Years Active: 1996-2011
Title: Innovations and Contributions of Inventor Gunnar Aberg
Introduction
Gunnar Aberg, an accomplished inventor based in Sarasota, FL, has made significant strides in the field of pharmaceuticals with a total of 13 patents to his name. His work focuses primarily on developing methods and compositions aimed at treating various medical conditions, particularly pulmonary disorders and neuropathic pain.
Latest Patents
Among Gunnar Aberg's most recent inventions is a patent for methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol. This innovative method employs the pure (R,R) isomer of formoterol, delivering potent bronchodilatory effects while minimizing adverse effects and the development of tolerance, thus increasing the duration of action compared to the racemic formoterol. Additionally, Aberg has patented methods of relieving neuropathic pain through the use of the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine. This invention highlights the therapeutic potential of S-isomers in inducing local anesthesia, analgesia, and promoting sleep.
Career Highlights
Gunnar Aberg has had a distinguished career within the pharmaceutical industry, having worked with notable companies such as Sepracor, Inc. and Bridge Pharma Inc. His innovative contributions have not only expanded the treatment options available for patients but have also positioned him as a key figure in pharmaceutical research and development.
Collaborations
Throughout his career, Aberg has collaborated with esteemed colleagues including John Morley and John R McCullough. These partnerships have further enriched his work and contributed to the advancement of his inventions in therapeutic methodologies.
Conclusion
Gunnar Aberg stands out as a notable inventor whose contributions to the science of treatment are marked by a dedication to improving the quality of life for patients suffering from pulmonary disorders and neuropathic pain. His continued innovation and collaboration suggest a promising future in pharmaceutical advancements.